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Abstract
Background: Herpes simplex type II (HSV-2) is a member of the family herpesviridae.
Human infection with this double stranded linear DNA virus causes genital ulcerative
disease and existing treatment options only serve to resolve the symptomatology
(ulcers) associated with active HSV-2 infection but do not eliminate latent virus. As a
result, infection with HSV-2 follows a life-long relapsing (active versus latent) course.
On the basis of a primitive bacterium anti-phage DNA defense, the restriction
modification (R-M) system, we previously identified the Escherichia coli restriction
enzyme (REase) EcoRII as a novel peptide to excise or irreversibly disrupt latent HSV-2
DNA from infected cells. However, sequences of the site specificity palindrome of
EcoRII 5’-CCWGG-3’ (W = A or T) are equally present within the human genome and
are a potential source of host-genome toxicity. This feature has limited previous HSV-
2 EcoRII based therapeutic models to microbicides only, and highlights the need to
engineer artificial REases (zinc finger nucleases-ZFNs) with specificity to HSV-2
genomic-DNA only. Herein, the therapeutic-potential of zinc finger arrays (ZFAs) and
ZFNs is identified and modeled, with unique specificity to the HSV-2 genome.
Methods and results: Using the whole genome of HSV-2 strain HG52 (Dolan A et
al.,), and with the ZFN-consortium’s CoDA-ZiFiT software pre-set at default, more
than 28,000 ZFAs with specificity to HSV-2 DNA were identified. Using computational
assembly (through in-silico linkage to the Flavobacterium okeanokoites endonuclease
Fok I of the type IIS class), 684 ZFNs with specificity to the HSV-2 genome, were
constructed. Graphic-analysis of the HSV-2 genome-cleavage pattern using the afore-
identified ZFNs revealed that the highest cleavage-incidence occurred within the
30,950 base-pairs (~between the genomic context coordinates 0.80 and 1.00) at the
3’ end of the HSV-2 genome. At approximately 3,095 bp before and after the 5’ and
3’ ends of the HSV-2 genome (genomic context coordinates 0.02 and 0.98,
respectively) were specificity sites of ZFNs suited for the complete excision of over
60% of HSV-2 genomic material from within infected human cells, through the
process of non-homologous end joining (NHEJ). Furthermore, a model concerning a
recombinant (ICP10-PK mutant) replication competent HSV-2 viral vector for
delivering and transducing a diploid copy (or pair) of the HSV-2-genome-specific ZFN
genotype within neuronal tissue, is presented.
Conclusion: ZFNs with specificity to HSV-2 genomic DNA that are precursors of
novel host-genome expressed HSV-2 gene-therapeutics or vaccines were identified.
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Herpes simplex virus type II as a cause of human genital ulcerative disease
Herpes simplex virus types I and II (HSV-1 and 2, respectively), together with the vari-
cella-zoster (chicken-pox) virus, are members of the herpesviridae taxonomic family of
viruses [1]. Human infection with these largely neuro-tropic viruses can be active or
latent [1,2]. Active infection with HSV-1 or HSV-2 leads to ulcerative lesions of the
oral or genital mucosa, respectively [3,4]; latent infection with these viral species is lar-
gely asymptomatic. Latent HSV-2 infection occurs primarily in neurons of the sacral
root ganglia. Therefore, the clinical spectrum of HSV-2 can be said to comprise pri-
mary-active infection, followed by resolution and establishment of a lifelong phase of
latency [4,5]. Primary HSV-2 infection is characterized by the appearance of blisters or
vesicles on the vulva or penis that break to leave shallow, painful ulcerating lesions
[6,7]. These ulcers spontaneously heal within 2-3 weeks, although healing can be very
slow in immunocompromised patients [7]. Latent-HSV-2 is characterized by recurrent
episodes of clinical disease (4-5 per year); the subclinical status intermittent between
reactivation episodes can be associated with infectious viral shedding and transmission
of HSV-2 in genital secretions. The incidence of symptomatic HSV-2 infections varies
geographically but is higher in HIV positive individuals [8-10]. The genital lesions asso-
ciated with active- HSV-2 infection have become a particular public health concern, as
there is evidence that links them to an increased risk of sexually-acquiring or transmit-
ting human immunodeficiency virus type I (HIV-1) [5-8]. Therefore, treatment for
HSV-2 and other genital ulcerative diseases [9] is an acceptable measure when consid-
ering reducing the risk of HIV-1 sexual transmission and acquisition [10-12].
Challenges in existing options for the treatment or prevention of HSV-2 acquisition
Existing biomedical interventions for HSV-2 treatment are only applicable to actively
replicating HSV-2 particles [13]. This limits their clinical relevance to only treating
ulcerative lesions of HSV-2 [14,15], rather than clearing the infection. Specifically, exist-
ing chemotherapy options for treating HSV-2 only inhibit actively replicating virus, while
latent virus is unaffected. However, the latent HSV-2 is the source of future episodes of
genital ulcerations following reactivation during or following a bout of immune suppres-
sion caused by a common cold, after infection with HIV or chemotherapy treatment,
among others [16,17]. This picture of a lifelong latent infection that can be reactivated
presents unique challenges for the biomedical management of HSV-2 infections [18].
There have been substantive efforts to develop an efficacious HSV-2 vaccine based on
existing biomedical evidence, and these are on-going [19,20]. Specifically, randomized
clinical trials of prior HSV-2 vaccine candidates, comprising single or double-component
(gB2 and gD2) recombinant glycoproteins formulated in adjuvants or expressed within
live-attenuated replication-incompetent (disable-infectious single cycle-DISC, ICP8 gene
mutation) or replication-competent (ICP10 gene mutation) HSV-2 derived viral vectors,
have only demonstrated partial efficacy towards the end goal of protecting against the
sexual transmission or acquisition of HSV-2 [21-25].
-Virology of HSV-2 and the concept of pre-integration viral-genome slicing (PRINT-vGSX)
Like the other generic members of the alphaherpesviridae subfamily, HSV-2 is a large,
enveloped virus with an outer lipid envelope studded with at least 10 viral
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an icosahedral nucleocapsid containing the double-stranded DNA genome [26]. The
complete sequenced genome of a strain of HSV-2, HG52 (Dolan et al. [27]), reveals
that HSV-2 genomic DNA is organized into two unique regions of double-stranded
DNA (long 126-kb and short 26-kb short) denoted as UL and US. These are bracketed
by inverted repeat sequences (TRL-IRL and IRS-TRS) that readily allow isomerization
and recombination of the two regions [27,28]. The entire genome has a G+C content
of 70.4%, and comprises 84 open reading frames coding approximately 74 proteins that
can be grouped into three categories: (i) immediate-early genes (whose transcription
depends on a virally-encoded activating protein, VP16, and which encode the viral a
proteins); (ii) early genes (which are turned on by the a proteins and whose products
(b proteins) are involved in DNA replication); and (iii) late genes, the products of
which (g proteins) are virion structural proteins and proteins required for virus particle
assembly and egress. The majority of the viral envelope glycoproteins (gD) are antige-
nically related to those of HSV-1, whereas gG1 and gG2 are type-specific [27,29]. This
array of numerous gene-products, many of which are indispensable for virus growth in
vitro, underlies the efficacious virulence evolved by HSV-2 towards the evasion of host
defenses including preventing apoptosis in the infected host cell, blockade of pathways
for interferon-induction and production, and down-regulation of HSV-2 antigen pre-
sentation under the context of type I Major-histocompatibility complex (MHC) [30].
On basis of the linear double stranded (ds)D N Ag e n o m i c - s t r u c t u r eo fH S V - 2[ 2 7 ]
and the functioning of the primitive anti-phage defense inherent within bacteria, the
restriction modification (R-M) system, the possibility of directly attacking and disrupt-
ing or excising HSV-2 genomic DNA has been proposed as an alternative, novel bio-
medical intervention against HSV-2 [31]. Specifically, we demonstrated that the
Escherichia coli restriction enzyme (REase)-EcoRII, which cleaves the HSV-2 genome
at more than 800, is an ideal precursor for excising sections of genomes of infectious
(actively replicating) HSV-2 particles or irreversibly disrupting latent-HSV-2 genomic
DNA from within infected cells. Sequences of the site specificity palindrome of EcoRII
5’-CCWGG-3’ (W = A or T) were noted to be prevalent within the human-host gen-
ome and therefore a source of host-genome toxicity. This finding limited the HSV-2/
EcoRII based therapeutic models to microbicides only [32,33], and highlighted the
requirement to engineer artificial REases (or zinc finger nucleases - ZFNs) [34-36] with
unique specificity to genome sequences of HSV-2 as safe precursors for therapeutic
exploration in-vivo.G r o s s eet al. [37], recently identified such HSV-1 specific homing
(mega-) endonucleases, demonstrating that their expression in African green monkey
kidney fibroblast (COS-7) and BSR cells inhibits infection by HSV-1 at low and moder-
ate multiplicities of infection (MOIs), inducing a significant reduction in the viral load.
Furthermore, the remaining viral genomes display a high rate of mutation (up to 16%)
at the meganuclease cleavage site, consistent with a mechanism of action based on the
cleavage of the viral genome. This work highlighted mega (and zinc finger) nucleases
as an alternative class of antiviral agent with the potential to address replicative and
latent DNA viral forms [37].
In this paper, the identification, assembly and modeling of the in-vivo therapeutic
potential of zinc finger arrays (ZFAs), ZFNs and viral vectors transducing the
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presented for the first time.
Results
Identification of HSV-2 genome specific zinc finger array (ZFAs) and zinc finger nucleases
(ZFN)
Us i n gt h eF A S T Af o r m a to ft h en u c l e o t i d es e q u e n c e so ft h ew h o l eg e n o m eo fH S V - 2
strain HG52 (Dolan et al. [27]) (provided in additional file 1) and CoDA-ZiFiT [34-36],
a proprietary computational software of theZ F N - c o n s o r t i u mt h a tw a sp r e - s e ta ti t s
default-user options, identification of over 28,000 ZFAs with specificity to HSV-2 geno-
mic DNA (see additional file 2) was achieved. Using computational assembly (based on
the in-silico linkage of the Zif arrays (ZFAs) to the Flavobacterium okeanokoites the
type II class endonuclease, FN (Fok I) as previously achieved in-vivo by Kim et al.
[38]), constructs of 684 ZFNs (hybrid, chimeric Zif-FN) with specificity to the HSV-2
genome (see additional file 3) was attained. Throughout the latter experiments, the
description of the spacer regions was maintained at 5-7 base-pairs. These ZFNs can
bind as dimers to their target HSV-2 DNA sites, with each monomer using its zinc fin-
g e rd o m a i nt or e c o g n i z ea‘half-site’ of the targeted DNA sequence. In-vivo, dimeriza-
tion of ZFNs is mediated by the FokI cleavage domain through cleavage of a five or six
base pair ‘spacer’ sequence that separates the two inverted target ‘half sites’ [34-36].
Importantly, since the DNA-binding specificities of zinc finger domains can be re-engi-
neered using various methods, customized ZFNs can, in principle, be constructed to
specifically target almost any gene sequence [34]. Three methods are currently avail-
able for engineering zinc finger domains: Context-dependent Assembly (CoDA), Oligo-
merized Pool Engineering (OPEN), and Modular Assembly [34-36]. Herein, the CoDA
approach, using the ZiFiT software based on work by researchers from the Barbas lab
[35], was employed for assembly of ZFAs and ZFNs. A list of four ZFNs, inclusive of
their -1 to 6 alpha-helical nucleotide binding and recognition domains (F1, F2/F3, F2,
F1) alongside the respective site specific sequence within the HSV-2 genome, are pre-
sented in table 1. Residues -1 to 6 (numbered relative to the start of the helix) of the
alpha-helix of the ZFAs are responsible for the specific recognition of triplets of DNA
sequences through the formation of base-specific contacts in the major groove of the
double-stranded target DNA [34-36]. Therefore, residues -1 to 6 within the ZFs’ alpha
helixes are denoted as ‘recognition’ residues and are listed in N- to C-terminal direc-
tion; all other residues in the ZF are called the ‘backbone’ [34-36]. As a consequence,
the recognition sequences of the ZFNs bind target DNA sites through amino acids -1
to 6 of the ‘recognition’ alpha helix in the 3’ to 5’ direction, a reverse-pattern that can
be confusing as the DNA target site is always referred to in the 5’ to 3’ direction,
whereas amino acid sequences are referred to from the N to C terminus. In this study,
there were ZFAs cleaving at every 5-9 bp within the linear-context of the HSV-2 gen-
ome. Graphic-analysis (Figure 1) of the HSV-2 genome cleavage-pattern by the identi-
fied 684 ZFNs revealed that the highest incidence of HSV-2 genomic cleavage was
situated within the last 30,950 base-pairs (154,784/5: ~between the genomic context
coordinates 0.80 and 1.00) at the 3’ end of the HSV-2 genome. That said, at approxi-
mately 3094.9 bp (30,950/10) before and after the 5’ and 3’ ends of the HSV-2 genome
(genomic context coordinates 0.02 and 0.98, respectively) another array of specificity
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of over 60% of HSV-2 genomic material from within infected latently human cells (see
additional files 4 and 5, respectively, and Table 1) through the process of non-homolo-
gous end joining (NHEJ), following the introduction of a double-strand break (DSB)
[39]. According to Dolan et al. [27], this targeted region comprises over 58 genes on
the UL region of the HSV-2 genome, inclusive of the (a) native-structural ones: a virion
glycoprotein gene (UL1), capsid protein genes (UL18, 35), tegument protein-genes
(UL46-49); and (b) others expressed-functionally: DNA polymerase genes (UL30, 42), a
DNA helicase-primase gene (UL52) and other indispensable genes.
Table 1 List of ZFNs cleaving within 3,094 bp located 5’ and 3’ of the HSV-2 genome
context
Zinc Finger Nuclease (ZFN) Left Fn; triplet- a-Helix Right Fn; triplet- a-
Helix
-target HSV-2-DNA site 5’
ZFN-unknown-SP-7-1
1 aGTCCCCGTCCTGCCGCGCGGGGGCGg 27 F1; EEANLRR; (GAC) F1; KRHTLTR;(GCG)
1t CAGGGGCAGGACGGCGCGCCCCCGCc 27 F2; RREHLVR; (GGG) F2; RREHLVR;(GGG)
F3; DPSNLQR; (GAC) F3; RTDSLPR; (GCG)
ZFN-unknown-SP-5-1
69 gCCCCGCGGCGCGCGGGGGGAGGGg 93 F1; RGNHLRR; (GGG) F1; KKDHLHR;(GGG)
69 cGGGGCGCCGCGCGCCCCCCTCCCc 93 F2; RTDTLAR; (GCG) F2; QSAHLKR; (GGA)
F3; ERRGLAR; (GCC) F3; RTEHLAR; (GGG)




F1; RRAHLQN; (GGG) F1; DGSTLRR;(GCC)
154647
cGGGACGGCGGGCGGGCGGCGGCGGc154672
F2; QSTTLKR; (GCA) F2; DSSVLRR;(GCC)




F1; RGNHLRR; (GGG) F1; RNTHLAR;(GGG)
154561
cGGGGCGCCGCGCGCCCCCCTCCCCg154586
F2; RTDTLAR; (GCG) F2; RQDNLG; (GAG)
F3; IRHHLKR; (GGT) F3;QQGNLQL; (TAA)
 
0.00                    0.20                     0.40                     0.60                  0.80                      1.00
Figure 1 Schematics of HSV-II genome- cleavage by ZFN. This figure graphically illustrates the sites and
frequency of ZFN cleavage of the HSV-2 genome by the 684 ZFNs identified. Cleavage was present at
almost all positions within the HSV-2 genome. Note, however, that the highest incidence of HSV-2
genomic cleavage is situated within the last 30,950 base-pairs (154,784/5: ~between the genomic context
coordinates 0.80 and 1.00) at the 3’ end of the HSV-2 genome. That said, at approximately 3,094.9 bp
(30,950/10) before and after the 5’ and 3’ ends of the HSV-2 genome (genomic context coordinates 0.02
and 0.98, respectively), there is another array of specificity sites for ZFNs that are potentially best suited for
the complete excision of over 60% of HSV-2 genomic material from within infected human cells.
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genome specific ZFN, genotype
Recombinant, conditionally-replicating Herpes simplex virus Type 1 (HSV-1) and II
(HSV-2) vectors for purposes of malignant glioma treatment [40] and HSV-2 vaccina-
tion [41-46], respectively, have been described previously. The majority of recombi-
nant-HSV-2-based vectors have yielded encouraging results in Phase I and Phase II
clinical trials [21-24,47,48]; while genetically modified-HSV-I-based vectors raise
safety-concerns around their potential to induce apoptosis in CNS neurons, causing
severe and often fatal encephalitis or epileptiform seizures in immune competent
humans. HSV-2 viral vectors are thought to be safe at this time.
Here, this modeling will focus on recombinant, yet replication competent, HSV-2
viral vectors for delivering and transducing a diploid copy (or pair) of the HSV-2 gen-
ome- specific- ZFN-genotype within neuronal tissue, to be used as a novel HSV-2
genomic-vaccine/therapy.
￿ Firstly, it was observed in accordance with Dudek and Knipe [42], that it is possible
to use two types of replication-impaired HSV mutant viral strains as vectors for HSV
vaccines, these being (a) replication-defective mutant strains and (b) single-cycle
mutant strains. Replication-defective mutants can infect cells and express immediate-
early and early viral gene products and several late gene products but contain defects
in viral DNA replication, so that their replication cycle is irreversibly blocked.
￿ Secondly, it was noted that two sub-types of HSV-2 replication-defective vectors
are equally possible. On one hand, Dudek and Knipe [42] have described HSV-2
mutant vectors defective for ICP8, demonstrating that these vectors express viral late
genes in absence of viral DNA replication, probably as ICP8 and/or a complex of viral
DNA replication proteins exerts an inhibitory effect on viral late gene expression in
the absence of viral DNA synthesis. On the other hand, Laing et al. [25] have pre-
sented two variants of HSV-2 vectors with deletions in the ICP10 genes. Among the
latter group of HSV-2 mutant vectors, the HSV-2 mutant ΔRR is deleted in the ICP10
RR domain for the enzyme ribonucleotide reductase, which is required for virus repli-
cation in neurons; the HSV-2 mutant ΔPK is deleted in only the protein kinase (PK)
domain of the large subunit of ribonucleotide reductase (R1, also known as ICP10)
[25,49-51].
To construct the proposed model-recombinant HSV-2 viral vector for delivering and
transducing the diploid copy of the HSV-2 genome specific ZFN-genotype it is sug-
gested that the StuI/BglII fragment encompassing the ICP10PK domain within the
HSV-2 mutant ΔRR previously described by Laing et al. [25], should be replaced by an
alternate pair of restriction enzymes’ franked fragments (specifically, the ZFN-consor-
tium’s preference of XbaI/NotI [34-36]) that encompass or accommodate a diploid
copy (or pair) of the HSV-2-specific-ZFN-genotype of interest (denoted as 2xZifHSV-2-
FN). The final construct, denoted as HSV-2ΔRR [ICP10PK- 2xZifHSV-2-FN] would con-
tain ICP10PK- 2xZifHSV-2-FN driven by the authentic ICP10 promoter, which is regu-
lated by IE kinetics (independent of virus replication) and responds to AP-1 [25,52,53].
The diploid copy (or pair) of ZFN is necessary, as ZFN operates as a dimer. In-vivo,
this dimerization is mediated by the FokI cleavage domain through cleavage of a five
or six base pair ‘spacer’ sequence that separates the two inverted target ‘half sites’
[34-36]. Pre-clinical testing for the efficacy and safety of this model vector is proposed
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molar excess using Lipofectamine (Invitrogen), with (test sample) or without (control)
prior transduction using our model-recombinant vector (HSV-2ΔRR[PK- 2xZifHSV-2-
FN]). Efficacy for ZifHSV-2-FN expression should be monitored using an ZifHSV-2-FN
specific ELISA, while the extent of infectious HSV-2 DNA abrogation can be measured
using RR-assays that will not detect viral vectors which are deleted for the RR-gene.
Safety can be monitored by measuring the extent of Vero-cell death using staining
with ethidium homodimer (Molecular Probes, Eugene, OR, USA), a fluorescent nuclear
stain in the red spectrum that penetrates dead cells and increases intensity after bind-
ing to DNA, as described by Laing et al. [25]. Stained cells are counted in five ran-
domly selected microscopic fields (at least 250 cells) and the percentage of apoptotic
cells is calculated relative to the total number of cells visualized by permeating the cul-
tures with 5% Triton X-100 for 30 s followed by incubation with the fluorescent
nuclear stain, DAPI (Sigma). Data are expressed as the mean percentage positive
cells ± SEM.
Discussion
This paper reports the first identification of ZFNs with specificity to HSV-2 genomic
DNA that are potential precursors for novel host-genome expressed HSV-2 gene-
therapeutics or vaccines. Based on the fact that infection with HSV-2 is associated
with an increased risk of HIV-1 acquisition and transmission [9,10], that existing treat-
ment options for HSV-2 only serve to resolve the symptomatology (ulcers) associated
with active-HSV-2 infection and do not eliminate latent-virus [13-15], and that there
are no clinically approved vaccines with substantiated efficacy for preventing HSV-2
infection [19-25], myself and various colleagues [31], using a primitive bacteria anti-
phage DNA defense, the restriction modification (R-M) system, previously identified
the Escherichia coli restriction enzyme (REase)-EcoRII as a novel peptide to excise or
irreversibly inactivate latent HSV-2 DNA from within infected cells. The high preva-
lence of sequences of the site specificity palindrome of EcoRII 5’-CCWGG-3’ (W = A
or T) within the human genome was noted to be a potential source of host-genome
toxicity. As a consequence, all previously modeled EcoRII-based HSV-2 therapeutics
were allocated for ex-vivo expression as topical applications or microbicides [32,33].
The consensus was that HSV-2 specific nucleases were required for in-vivo use, as
these would not cause potential human-genome toxicity. Grosse et al. [37] previously
identified homing (mega-) endonucleases specific to HSV-1 and demonstrated their
ability to inhibit HSV-1 infection in cultured cells. The hybrid ZFAs (additional file 2)
and ZFNs (additional file 3) identified here have unique specificity for HSV-2 genomic
sequences (additional file 1and Figure 1). Therefore, they too may offer a safer alterna-
tive to EcoRII, particularly as they can be expressed in-vivo with no or minimal risk of
toxicity to the host-genome.
Zinc fingers (Zif or ZF), like those specific to the nucleotide sequences of the com-
plete HSV-2 genome (provided in additional file 1) presented in additional file 2, are
protein motifs capable of targeted DNA-binding [34-36]. Each individual zinc finger
usually recognizes three nucleotide bases, but many zinc fingers can be combined to
generate an array capable, in the case of our listed ZFAs of three fingers, of recogniz-
ing nine nucleotides [54-57]. Owing to this unique ability to target and bind to a
Wayengera Theoretical Biology and Medical Modelling 2011, 8:23
http://www.tbiomed.com/content/8/1/23
Page 7 of 13specified nucleotide sequence, zinc fingers have previously been used to direct small
molecules into unique sequences within the human genome including genes of inte-
grated viruses [58,59]. For example, inhibition of HIV replication in-vivo using small
artificial molecules modified to harness target DNA, a binding mechanism inherent in
zinc finger (ZF) domains as a strategy to repress HIV transcription, has previously
been reported by Segal et al. [58] and Eberhardy et al. [59]. Despite these reports, and
that by Grosse et al. [37] concerning homing (mega-) endonucleases specific to HSV-1,
ZF-nuclease-based disruption or abolition of HSV-2 genomes has yet to be reported.
The latter ZFNs, like the 645 HSV-2 genome specific ones presented in Table 1 and
additional files 2, 4 and 5, are artificial hybrid (chimera) restriction endonucleases con-
structed by covalently linking the DNA-binding domains of an array of 3-6 zinc fingers
on to the non-specific DNA cleavage domain (or simply FN) of the Flavobacterium
okeanokoites bacteria restriction endonuclease, FokI [34-36]. In-vivo, as noted above,
the zinc finger nucleases function as dimers (or pairs) [54-57]. Therefore, considering
our three ZF array based ZFNs, eighteen (9 × 2) or more (plus the 5-7 spacer-
sequence) nucleotide base pairs will be recognized and cleaved. As a result, unlike the
five base-pair specificity palindrome of EcoRII {5’-CCWGG-3’ (W = A or T)} [31],
ZFNs possess longer (> 18 bp) sequence recognition abilities, a unique feature that
endows ZFNs with more target-specificity to HSV-2 genomic DNA, without risking
off-target damage to host genomic DNA. Although the ZFNs identified in Table 1 are
specifically proposed for excision of over 60% of the HSV-2 genomic DNA from
infected host cells through NHEJ, it is possible to alternatively target and disrupt HSV-
2 virulence genes using those ZFNs that cleave several times within the contextual
position corresponding to the target-gene of interest (see additional file 3 for all ZFNs
cleaving within the HSV-2 genome), although there are questions surrounding these
propositions.
One may argue that excision of 60% or more of HSV-2 DNA in the host genome can
not structurally abolish latency (RL, US and RS regions remain largely unaffected),
despite functionally disabling the virus due to deletion of several vital structural and
functional genes located within the deleted target UL-region. As a consequence, the
ultimate fate of the residual 40% HSV-2 DNA (RL, US and RS regions) warrants expla-
nation. For instance, since the HSV-2 genome content occasionally exists in doublex
[27], it can be argued that the residual 40% HSV-2 DNA, alone or in association with
DSB by-products [34-38,53-57], presents a potential source of homologous recombina-
tion (HR) and/or repair of the HSV-2 genome-cleavage products. This underlines the
requirement for in-vivo data to evaluate the long-term effects on the host and the
HSV-2 genome, and of using ZFNs as in-vivo therapeutics using methods similar to
those proposed above. The coverage and efficiency of gene delivery and transduction
by the advanced model-delta-RR vectors remains questionable and requires focused
experimental evaluation. Specifically, it remains unclear which cells (latent genome is
retained in a fraction of the sensory neurons) will be therapeutically targeted and mod-
i f i e d ,a n dt ow h a te x t e n t .F o re x a m p l e ,i fs ensory neuronal cells are heterogeneously
targeted and not homogenously transduced to the necessary-efficacious extents, one
may argue that the less-effected neuronal cells could be a source of new virus that
could result in recombination and re-established latency. The exact modus of clinical
administration and use of the proposed model-delta-RR vectors to deliver the diploid
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mal injection may be possible. This carries the potential risk of off-target gene-delivery,
to epithelial cells for example, and further emphasizes the need for preclinical studies
a n dt r a i l s .I tm a yb ea r g u e dt h a tr e s i s t a n c et oZ F N sc o u l da r i s et h r o u g hm u t a t i o n s .
However, such mutations can not simply be single-point mutations, as is the case with
those that cause resistance to REase activity. As early as 1984, Brown et al. [60]
demonstrated that several HSV-2 mutants with cumulative restriction site deletions in
one of the repeats (TRL or IRL) have a measurable growth disadvantage relative to
wild-type virus in tissue culture. Therefore, it is can be argued that any attempt to
accumulate mutations in the over 23 bp (18 palindrome bp, 9 for each ZFN dimer;
plus a 5 bp-spacer) sequence targeted by the ZFNs could exert deleterious effects on
the survival and replication of the mutant isolate of the HSV-2. Moreover, existing evi-
dence from Grosse et al. [37] and Cradick et al. [61], who have previously identified
HSV-1 specific homing (mega-) endonucleases and demonstrated their inhibition of
HSV-1 infection in cultured cells, shows that artificial mega-nucleases (zinc finger
nucleases) mediated mutagenesis offers a novel therapeutic strategy for targeting HSV-
1 and episomal Hepatitis B Virus DNAs, respectively, and clearly supports these propo-
sitions. The design of specific ZFNs for in-vivo use may require further improvement,
say-with more than the 3 zinc finger arrays (4-6, to be exact) [54]. In addition, the effi-
ciency of ZFN cleavage could be improved by further optimization [54] and modifica-
tions to the cleavage domain, as Doyon et al. [62] previously demonstrated in order to
generate a hybrid capable of functionally interrogating the ZFN dimer interface to pre-
vent homodimerization, while enhancing the efficiency of cleavage. A number of other
concerns may be cited concerning the use of the proposed vectors (the advanced
model of recombinant HSV-2 vectors carrying and delivering the desirable therapeutic
diploid copy (pair) of the genotype of HSV-2-genome-specific-ZFNs (HSV-2ΔRR [PK-
2xZifHSV-2-FN])) in a clinical setting. For example, it can be argued that using vectors
constructed from a basic-core of HSV-2 genes may render the genomes of these viral
vectors susceptible to cleavage by the HSV-2-genome specific-ZFNs they carry, if the
vectors are replication competent. Here, we suggest that use of viral vector constructs
that are defective of HSV-2 genomic DNA (amplicons) could replace the HSV-2 core-
gene vectors, and eliminate this possibility. Alternatively, although several clinical trials
concerning HSV based viral vectors have been conducted and demonstrated their
safety [40-46], no clinical trial-data exists concerning the safety of our proposed and
modeled HSV-2 viral vectors that deliver and transduce the diploid copy or pair of the
HSV-2 genome-specific ZFN genotype. Therefore, data concerning safety and efficacy
of the advanced model-vectors is required before this model is clinically used in
humans.
In conclusion, this research has identified ZFNs with specificity to HSV-2 genomic
DNA. These HSV-2 genome-specific-ZFNs present ideal precursors for use as novel
host-genome expressed HSV-2 gene-therapeutics or vaccines. Specifically, using the
advanced model of recombinant HSV-2 vectors carrying and delivering a diploid copy
(or pair) of the desirable therapeutic genotype of the HSV-2-genome- specific-ZFNs
(HSV-2ΔRR [PK- 2xZifHSV-2-FN]), it may be possible to irreversibly inactivate infec-
tious HSV-2, through excision of over 60% of its genomic DNA or targeted disruption
of specific virulence genes.
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FASTA format of the nucleotide sequences of the whole genome of HSV-2 strain
HG52 (Dolan et al. [27]) (provided in additional file 1; the NCBI accession number
provided at end) and the Zinc-Finger Nuclease-Consortium’s software CoDA-ZiFiT
[34-36] (see software and availability section for URL link).
Interventions
T h eF A S T Af o r m a to ft h en u c l e o t i d es e q u e n c e so ft h eH S V - 2g e n o m ew e r ef e di n t o
the user interfaces of CoDA-ZiFiT-ZFA and the CoDA-ZiFiT-ZFN, both of which
were pre-set at default, with a spacer-option of 5-9 bp selected for the latter.
Measured variables
Lists of ZFAs and ZFNs, inclusive of graphic maps of their action in the genomic con-
text of HSV-2, were generated as per the user protocol [34-36].
Modeling the prototype recombinant HSV-2 viral vector delivering and transducing HSV-
2 genome-specific-ZFN genotype
A review of available relevant literature [25,41-50] concerning HSV-2 viral vectors was
carried out, as is sequentially described in the respective results’ sub-section above.
Software and database availability
- The ZFN consortium CoDA-ZiFiT-ZFA/ZFN software and algorithms used are
available at the following url: http://www.zincfingers.org/scientific-background.htm
- The NCBI viral genome database hosting the complete HSV-2 genome used, is
available at the following url: http://www.ncbi.nlm.nih.gov/genomes/Genome-
sHome.cgi?taxid=10239
Accession numbers
T h eN C B Ig e n ei d e n t i t yo ft h ec o m p l e t eH S V -2 strain HG52 used in this study is: |
NC_001798|, and gene-bank identity (gi) is |6572414|emb|Z86099.2|. Sequencing Cen-
ter: A. Dolan, MRC Virology Unit, Church Street,, Glasgow,, G11 5JR, UK
Additional material
Additional file 1: A detailed list of the 154,746 nucleotide bases within the HSV-2 genome used. This file
offers FASTA-format listing of the 154,746 nucleotide bases within the HSV-2 strain HG52 genome used, as
deposited in the NCBI viral genome database by Dolan et al. [27].
Additional file 2: A detailed list of some of the over 28,000 Multi-Zif assembly as specific to the HSV-2
genome. This file lists the Multi-Zif assembly specific to the first 1, 478 nucleotide sequences within the genomic
context of HSV-2 from bp 1 to 8,174.
Additional file 3: A list of the 684 ZFN that are specific to the HSV-2 genome. This file details the entire list
of the 684 ZFN that are specific to the HSV-2 genome along with their specificity positions or sites of clevage.
Additional file 4: A list of the -1 to 6 recognition domians of the alpha-helix for some of the ZFN cleaving
within the 3,094.9 bp at the 5’ end of the HSV-2 genome. This file lists details of the -1 to 6 recognition
domians (denoted F1, F2, F3/F3, F2, F1) of the alpha-helix for some of the ZFN cleaving within the 3,094.9 bp at
the 5’ end of the HSV-2 genome.
Additional file 5: A list of the -1 to 6 recognition domians of the alpha-helix for some of the ZFN cleaving
within the 3,094.9 bp at the 3’ end of the HSV-2 genome. This file lists details of the -1 to 6 recognition
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